BackBRAIN Biotech AG Overview
BRAIN Biotech AG

BRAIN Biotech AG Return on Equity

BRAIN Biotech AG (BNN.DE) has a ROE of 204.79%, above the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

204.79%

Return on Equity

204.79%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

BRAIN Biotech AG (BNN.DE) FAQ

BRAIN Biotech AG posts a ROE of 204.79%. That is above the Healthcare sector average of 13.1%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near 13.1% is typical. BRAIN Biotech AG's 204.79% is higher that level. That is roughly 1462.8% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

BRAIN Biotech AG's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 204.79%; use YoY and peer views to separate noise from signal.

Context for BNN.DE's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.1%), and (3) consistency with growth and profitability. This page covers the first two; BRAIN Biotech AG's other metric pages and overview cover the third.

Judging BRAIN Biotech AG against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 204.79% here, then scan peer and history charts to see if the gap is persistent.

Questions & Answers